Association between exposure to Efavirenz and substrates of dysrhythmia in HIV-infected young adults

Zahra Hosseini MD1 | Reza Mollazadeh MD1 | Seyed-Ali Dehghan-Manshadi MD2 | Mehrnaz Mohebi MD3 | Masoud Eslami MD1 | Seyed-Ali Sadre-Bafghi MD3 | Ali Akbari BS4 | Saeed Ghodsi MD1

1Department of Cardiology, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran
2Department of Infectious and Tropical diseases, HIV-AIDS Research Center, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran
3Department of Research, Tehran Heart Center, Tehran University of Medical Sciences, Tehran, Iran
4Biomedical Engineering Hill-Rom (Mortara) Sale and Technical Expert, Iranbehdasht Co, Tehran, Iran

Correspondence
Saeed Ghodsi, Department of Cardiology, Tehran Heart Center, Tehran University of Medical Sciences, Tehran, Iran.
Email: dsaeedgh@gmail.com

Abstract

Background: Dysrhythmia and sudden cardiac arrest occur more likely in HIV patients than healthy subjects. Thus, we need to examine dysrhythmias adverse effects of medications including Efavirenz as early as possible especially in young subjects.

Hypothesis: Efavirenz might have contributed to increased risk of developing common types of dysrhythmia in young HIV infected patients.

Methods: We performed a retrospective cohort study among 62 patients on Efavirenz and 38 controls. All participants were under 40 years old without cardiovascular disease. Total significant dysrhythmia in 24-hour ECG monitoring was the primary endpoint determined as the composite of high premature ventricular contraction (PVC) (>500 beats per 24 hours), high premature atrial contraction (PAC) (>500 bp24h), sinus pause, atrioventricular blocks, ventricular tachycardia, prolonged QTc, and low heart rate variability (HRV). Modified composite dysrhythmia consisted of low HRV (SD of normal-to-normal [SDNN]), high PVC and prolonged QT.

Results: Mean heart rate, Efavirenz regimen, male gender, and CD4 count predicted total dysrhythmia. Odds ratios were 1.108, 2.90, 4.36, and 0.96, respectively. The incidence of total dysrhythmia, high PVC, high PAC, low HRV (SD of normal-to-normal [SDNN]), high PVC and prolonged QT were 54.8%, 41.85%, 9.71%, 45.2%, and 12.9% in patients on Efavirenz against 42.11%, 31.64%, 0%, 34.2%, and 7.91% in controls, respectively ($p$-values: .031, .001, <.0001, .063, and .043 respectively). Modified composite dysrhythmia was also more frequent in Efavirenz group than that of control group (69.42% vs. 52.60%, respectively p = .032).

Abbreviations: AIDS, acquired immunodeficiency syndrome; ART, anti-retroviral treatment; AVB, atrioventricular block; bpm, beats per minute; bp24h, beats per 24 hours; CD4, cluster determinant-4; CRP, C-reactive protein; ECG, electrocardiogram; HIV, human immunodeficiency virus; HRV, heart rate variability; INSTIs, integrase strand transfer inhibitors; IL-6, interleukin 6; ms, milliseconds; NNRTIs, non-nucleoside reverse transcriptase inhibitors; NRTIs, nucleoside reverse transcriptase inhibitors; PAC, premature atrial contraction; PI, protease inhibitors; PVC, premature ventricular contraction; SDANN, standard deviation of the average normal-to-normal (NN) 5-minutes intervals; SDNN, standard deviation of normal-to-normal (NN) intervals; VO2 max, volume of O2 consumption; VT, ventricular tachycardia.

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

© 2021 The Authors. Clinical Cardiology published by Wiley Periodicals LLC.
# INTRODUCTION

Since the start of the HIV-AIDS outbreak, more than 70 million virus-infected subjects have been diagnosed and nearly 35 million patients have died. According to the WHO, 36.9 million (31.1–43.9 million) individuals lived with HIV at the end of 2017.¹ In Iran, the number of infected persons surpasses 60,000 and 37,000 suffer from diseases in the HIV-AIDS spectrum. The number of patients on appropriate treatment approximates 24,000.² Cardiovascular diseases are now the leading cause of death. Sudden cardiac death accounts for 5%–15% of cardiovascular deaths associated with HIV-AIDS in the United States, which is assumed approximately 4.5 times higher than expected.³ Antiretroviral therapy (ART) have markedly improved survival and quality of life. ART subtends four major categories including non-nucleoside reverse transcriptase inhibitors (NNRTIs), nucleoside reverse transcriptase inhibitors (NRTIs), integrase strand transfer inhibitors (INSTIs), and protease inhibitors (PIs). An optimal therapeutic protocol usually consists of two NRTIs combined with one drug from the remaining categories.⁴ Efavirenz is still one of the most commonly used NNRTIs suggested as a first-line option.⁴ There is a wide variety of cardiovascular potential adverse effects related to ART medications.⁶ However, evidence about increased cardiovascular events or dysrhythmia in patients receiving NNRTIs especially Efavirenz is not enough.⁷,⁸ Meanwhile we do not have sufficient publications about different types and mechanisms of dysrhythmia in those under Efavirenz treatment. Thus, as a first step we need to evaluate surrogate outcomes such as prolonged QT, which may be precursors of dysrhythmic events. Sudden cardiac death in HIV-infected patients is linked to previous myocardial infarction, cardiomyopathy, dysrhythmia, and structural heart disease. Of these etiologies, dysrhythmias particularly ventricular tachycardia, may lead to sudden cardiac death in those without evident cardiovascular disease.⁹ This study investigates all electrocardiographic features attributable to regimens with and without Efavirenz in patients with no apparent prior cardiovascular disease.

# METHODS

## Study participants

This retrospective cohort study was conducted in HIV-infected patients registered in the electronic database of Iranian Research Center for HIV-AIDS (IRCHA). Data from 1789 consecutive patients below 40 years of age was extracted according to ID codes. Of these, 23 patients had died before the study started and follow-up data of 46 patients was missing. Individuals co-infected with Tuberculosis, hepatitis-C and/or B were not eligible. Likewise, those with concomitant malignancies, diabetes, hypertension, previous history of cardiovascular diseases including dysrhythmia, family history of sudden cardiac death, and chronic kidney disease were excluded. Current smokers, opiate users, and patients with one or more crossovers of treatment regimens were also excluded. Subjects who stopped treatment for 6 months or longer or did not attend more than four follow-up visits were excluded. We only enrolled healthy patients (regardless of HIV) who were not under treatment by medications other than ART. Patients were excluded if they had anemia or history of alcohol drinking. Furthermore, none of the participants had elevated blood pressure at baseline records or during visit at the clinic. Ultimately, 134 patients were eligible to participate in the study. Of these subjects, 34 patients either refused to participate in the study or did not have complete baseline data. Thus, a total of 100 patients remained in the study including 62 subjects with and 38 ones without history of receiving Efavirenz.

## Study design

A retrospective cohort scheme was accomplished among HIV infected patients aged under the age 40. We sought to investigate the presence of any clinically significant dysrhythmias or their precursor conditions. Hence; all patients who agreed to sign informed consent were visited at cardiology clinic. A comprehensive clinical history regarding cardiovascular disease, medications, hospital admissions, family history of cardiac disorders including sudden arrest was obtained. Thereafter a relevant physical examination accompanied with performing echocardiography were conducted. An ECG Holter monitoring was performed for 24 hours in all participants to evaluate the prevalence of dysrhythmia. All patients were using ART medications while we performed Holter monitoring and the therapeutic regimens continued thereafter. Participants were instructed not to consume caffeine since 24 hours before ECG Holter monitoring. Moreover, they were asked to have their casual daily activities and to avoid moderate or vigorous exercise as well as anxiety. An independent electrophysiologist with collaboration of a cardiologist performed interpretation of 24 hour ECG Holter monitoring results. All patients were assessed over a period of 1 month. Baseline laboratory tests such as HIV viral load and CD4 count were collected using the database of our HIV research.
center. Viral load (as copy numbers) and CD4 counts are markers that help to evaluate the efficacy of treatment and to adjust for the effect of the disease phase. All patients underwent echocardiographic evaluation at baseline and after Holter-monitoring in order to detect any considerable structural heart disease.

### 2.3 Definitions

Primary endpoint of the study was total significant dysrhythmia. It was defined as a composite of frequent premature ventricular contraction (PVC) (>500 bp24h), high premature atrial contraction (PAC) burden (>500 bp24h), sinus arrest, atrioventricular blocks, ventricular and supraventricular tachycardia, prolonged QTc, and low heart rate variability (HRV) (low SD of the average normal-to-normal [SDANN]). In addition, we defined another modified composite endpoint which consisted of low SD of normal-to-normal (SDNN), prolonged QT, and frequent PVC. These components seem to have greater clinical relevance with Efavirenz. High burden of ectopic beats (>500 bp24h) was determined according to prior studies. We Decreased adjusted HRV was determined as SDNN under 50 ms or SDANN values below the fifth percentile. SDNN represents SD

### TABLE 1 Baseline characteristics of the study participants with respect to Efavirenz regimen

|                | Non-Efavirenz (n = 38) | Efavirenz (n = 62) | p-value |
|----------------|------------------------|-------------------|---------|
| Age            | 34.47 ± 5.38 (32.71–36.24) | 35.31 ± 4.51 (34.16–36.45) | .54     |
| Sex (male)     | 60.51% (23)            | 66.1% (41)        | .082    |
| NRTI           | 97.36% (37)            | 98.38% (61)       | .68     |
| INSTI          | 5.26% (2)              | 6.45% (4)         | .152    |
| PI             | 76.31% (29)            | 62.90% (39)       | .012    |
| BMI (kg/m²)    | 30.47 ± 3.76 (26.71–42.68) | 32.47 ± 5.16 (23.71–45.24) | .85     |
| *Follow-up time 1 (duration of active treatment) | *6.25 (2–9) | *4.5 (1.5–7) | .19     |
| *Disease duration (duration since diagnosis of HIV infection) | *7.75 (2.5–9.5) | *6.5 (2–8) | .31     |
| CD4 count      | 600.78 ± 73.81 (519.21–682.36) | 570.61 ± 123.51 (497.93–641.25) | .58     |
| *Final viral load | 1587.60 ± 93.70 (543.30–10618.51) | 2134.5(450)* 1036.60 ± 58.30 (447.30–8629.81) | .47     |
| GFR (ml/min/1.73 m²) | 108.11 ± 12.34 (76.65–136.18) | 102.76 ± 18.09 (68.05–143.53) | .78     |
| Baseline QTc   | 435.12 ± 22.04 (385.65–511.14) | 428.02 ± 26.84 (378.60–501.64) | .58     |
| Mean heart rate | 81.42 ± 9.52 (78.29–84.55) | 81.38 ± 7.194 (79.59–83.25) | .41     |

Note: Continuous variables are expressed as Mean ± SD (95% CI) or Median (Interquartile range) if * is assigned to the variable. Abbreviations: BMI, body mass index; CD4, cluster determinant 4; GFR, glomerular filtration rate; INSTI, integrase strand transfer inhibitor; NRTI, nucleoside reverse transcriptase inhibitor; PI, protease inhibitor.

### TABLE 2 Multivariate logistic regression to evaluate the association of adjusted effects of independent predictors of Total significant arrhythmia

| Predictors of composite endpoint | Odds ratio 1 | 95% CI for OR | p-value | Odds ratio 2 | 95% CI for OR | p-value |
|--------------------------------|-------------|---------------|---------|-------------|---------------|---------|
| Age (per 5 years increase)     | 1.09        | (0.961–1.247) | .227    | 1.074       | (0.959–1.204) | .216    |
| Longevity of treatment (>5 vs. <5 years) | 0.92 | (0.231–1.83) | .371    | 1.087       | (0.951–1.242) | .222    |
| Mean HR (per 10 bpm increase)  | 1.187       | (1.075–1.312) | .001    | 1.108       | (1.033–1.190) | .004    |
| Efavirenz                      | 2.46        | (1.23–6.084)  | .031    | 2.90        | (1.062–7.921) | .038    |
| Sex (male vs. female)          | 4.357       | (1.34–14.13)  | .014    | 4.357       | (1.234–8.469) | .017    |
| Protease inhibitor             | 0.422       | (0.039–4.56)  | .477    |             |               |         |
| CD4 count (per 100 units increase) | 0.96 | (0.88–1.601) | .058    |             |               |         |

Note: Odds ratio 1 shows values after multiple adjustments for other ART medications (INSTI and NRTI), body mass index, hemoglobin level, baseline LV ejection fraction, and final viral load of HIV. Odds ratio 2 represents the likelihoods with adjustments mentioned above in addition to considering baseline QT interval in 12 lead ECG, and renal function (GFR).
of NN intervals whereas SDANN refers to the standard deviation of the averages of NN intervals in all 5 minutes segments of the ECG.\textsuperscript{12} QT intervals were calculated using the baseline ECG. Corrected QT intervals were calculated via the Bazett’s formula.\textsuperscript{13} Various sex-based cutoff points have been suggested to discriminate patients with prolonged QT based on different calculations. However, there is a general agreement about values of the Bazett’s formula as QT > 450 ms, and QT > 460 ms in males and females, respectively.\textsuperscript{14} Glomerular filtration rate (GFR) was calculated with the modification of diet in renal disease formula.\textsuperscript{15}

### Table 3

| Clinical and electrocardiographic outcomes with respect to Efavirenz consumption stratified by different subgroups |
|----------------------------------------------------|
| **Non-Efavirenz (%)** | **Efavirenz (%)** | **p-value** |
| Total significant dysrhythmias | 42.11 | 54.8 | .031 |
| Male | 6.67 | 51.22 | <.0001 |
| Female | 65.22 | 61.90 | .32 |
| TD < 5 years | 35.74 | 44.19 | .047 |
| TD > 5 years | 45.83 | 67.86 | .035 |
| Frequent PVC | 31.64 | 41.85 | .001 |
| Male | 13.30 | 43.90 | <.0001 |
| Female | 43.48 | 38.10 | .37 |
| TD < 5 years | 14.3 | 35.38 | .025 |
| TD > 5 years | 41.7 | 50.03 | .091 |
| Frequent PAC | 0.0 | 9.71 | <.0001 |
| Male | 0.0 | 14.61 | <.0001 |
| Female | 0.0 | 0.0 | NA |
| TD < 5 years | 0.0 | 14.7 | <.0001 |
| TD > 5 years | 0.0 | 3.60 | .350 |
| Low HRV* (SDANN<5th percentile) | 23.72 | 24.26 | .28 |
| Male | 0.0 | 19.51 | <.0001 |
| Female | 39.13 | 33.33 | .14 |
| TD < 5 years | 7.13 | 14.71 | .16 |
| TD > 5 years | 33.34 | 35.70 | .86 |
| Low HRV* (SDNN<50) | 34.2 | 45.2 | .063 |
| Male | 13.3 | 48.8 | <.0001 |
| Female | 43.4 | 42.8 | .515 |
| TD < 5 years | 35.7 | 41.2 | .15 |
| TD > 5 years | 33.3 | 50.0 | .016 |
| Prolonged QT | 7.91 | 12.90 | .043 |
| Male | 0.0 | 9.80 | .012 |
| Female | 13.04 | 19.05 | .335 |
| Tx < 5 years | 14.29 | 2.94 | .143 |
| Tx > 5 years | 4.2 | 25.0 | <.0001 |
| AV block (second/third degree) | 8.70 | 11.96 | .41 |
| Male | 0.0 | 2.44 | .54 |
| Female | 8.70 | 9.52 | .93 |
| VT | 0.0 | 0.0 | NA |
| Sinus pause/sinus arrest | 5.33 | 6.54 | .78 |

Abbreviations: AV, atrioventricular; HRV*, heart rate variability; NA, not applied; PVC, premature ventricular contraction; SDANN, SD of the average normal-to-normal (NN) 5-minutes intervals; SDNN, SD of normal-to-normal (NN) intervals; TD, Treatment duration; VT, ventricular tachycardia.

#### 2.4 Statistical analysis

Continuous variables are expressed as mean ± SD while categorical variables are presented as number and/or percentages. Two-tailed student’s t-test and Mann–Whitney U test were used to compare continuous variables with and without normal distribution, respectively, and the other statistical tests were used to detect differences in categorical variables. Multivariate logistic regression was applied to define independent predictors of total significant dysrhythmia. p values less than .05 were considered significant. We performed the
| Predictors of composite endpoint | OR 1 (univariate) | 95% CI       | p-value | OR 2 (multivariate) | 95% CI     | p-value |
|---------------------------------|------------------|--------------|---------|---------------------|------------|---------|
| Age (per 5 years increase)      | 1.14             | (0.83–1.54)  | .430    | 1.05                | (0.94–1.18)| .172    |
| Longevity of treatment (>5 vs. <5 years) | 1.71             | (1.02–2.33)  | .021    | 1.214               | (1.04–1.41)| .012    |
| Mean HR (per 10 bpm increase)   | 1.32             | (1.11–1.85)  | .005    | 1.105               | (1.027–1.18)| .007    |
| Efavirenz                       | 2.76             | (1.20–8.15)  | .028    | 2.13                | (1.14–6.02)| .011    |
| Sex (male vs. female)           | 3.65             | (1.04–9.18)  | .037    | 1.750               | (0.65–4.72)| .274    |
| Viral load                      | 1.82             | (0.76–5.41)  | .292    | 1.09                | (0.86–2.65)| .216    |
| CD4 count (per 100 units increase) | 0.91             | (0.73–1.72)  | .081    | 0.95                | (0.55–1.05)| .054    |

Note: Odds ratio 1 shows univariate logistic regression. Odds ratio 2 considers multiple adjustments for ART drugs (INSTI, PI, and NRTI), body mass index, baseline LV ejection fraction, baseline QT interval in 12 lead ECG, final viral load, and renal function (GFR).

**FIGURE 1** Frequencies of composite endpoints based on comparison between Efavirenz and non-Efavirenz regimens with further subgroup analysis. (A) Depicts the prevalence of Total significant dysrhythmia. (B) Represents distribution of the Modified composite endpoint, which consists of three components including low HRV (SDNN), frequent PVC, and prolonged QTc. TD refers to treatment duration. CD4, cluster determinant 4. A subgroup with p-value <.05 is marked via *
3 | RESULTS

The mean age of the patients was 34.22 ± 5.11 years and the median treatment length (follow-up) was 6.31 years. Sixty-two participants were on treatment with Efavirenz-containing regimens and 38 subjects received non- Efavirenz regimens. Table 1 presents the baseline general characteristics of the two groups. The majority of the patients (98%) used NRTI drugs whereas only 6% were on INSTIs. About 68% of the participants were treated with PIs. Baseline left ventricular ejection fractions (LVEF) of the subjects with and without Efavirenz were similar (median values were 52.5% and 55% respectively, \( p = .64 \)). Patients in this study were asymptomatic. None of them had experienced chest pain, exertional dyspnea, peripheral edema, palpitations, orthopnea, and syncope. All of them underwent Echocardiography, which did not reveal structural heart disease including regional wall motion abnormalities. Follow-up echocardiography revealed preserved LVEF and normal right ventricle function in all participants. Ejection fractions were identical on follow-up (median values were 55 for both groups with a \( p \)-value of .85). Table 2 shows the significance of different predictors of the composite endpoint, that is, total significant dysrhythmia, regarding multiple adjustments, which resulted in two models. Table 3 presents the cumulative prevalence of primary and secondary endpoints according to subgroups of gender and treatment duration. There were two cases with uncommon dysrhythmias, which were found incidentally. One had asymptomatic intermittent manifestation of a delta wave. The other patient had prominent alterations in the amplitude and direction of T waves known as T-wave alternans. No episodes of sustained or non-sustained VT occurred, not even in the subgroup of patients with prolonged QT intervals. Prolonged QT interval was more frequent in men who did not use PIs although the difference was not significant (10% vs. 6.2%, \( p = .24 \)). Treatment with PIs tended to be associated with fewer events of total dysrhythmia (54% vs. 42%, \( p = .065 \)).

Table 4 presents univariate and multivariate analysis pertaining to the predictors of modified composite endpoint. Furthermore, Figure 1 illustrates the differences between the two composite endpoints according to observed frequencies in subgroups.

4 | DISCUSSION

We focused on QT prolongation, PVC, PAC, brady-arrhythmia, and decreased HRV which mediate development of potentially malignant dysrhythmia such as VT. We found that patients on Efavirenz had increased prevalence of high PVC, high PAC, and total significant dysrhythmia than those not treated with Efavirenz. Similar rates of low HRV were detected in both groups. Prolonged QTc were observed in both groups. There is controversy about the impact of Efavirenz on QT length regardless of its subsequent clinical manifestations.6\textsuperscript{-19} Nevertheless, most studies such as the one by Charbit et al., found that prolonged QT is associated with conventional factors as well as chronicity of HIV infection rather than with ART drugs.20 We found that Efavirenz regimen increased the length of corrected QT interval overall and in males while females were not affected. Indeed, male subjects on Efavirenz were more likely to have prolonged QT (9.80% vs. 0%) as compared to non-Efavirenz men. Impact of Efavirenz on QT is not well established. Few studies have noticed about that Efavirenz might prolong QT interval, which is in line with our results.21 Conversely, prolonged QTc was more frequent in females than in males irrespective of Efavirenz use. Different regulation of potassium channels called Ik\textsubscript{r} (rapidly activating delayed rectifier) is well established in women compared with men. This is concordant with many reports such as the study by Hreiche and co-workers.22

The pathophysiology underlying QT prolongation by ART drugs is not well understood. However, decreased outward potassium, currents over the second phase of action potential has been proposed. Low expression of the human Ether-a'-go-go related gene (HERG) might control these potassium-rectifier channels which leads to extended repolarization.23 Then, prolonged QTc may serve as a preliminary state to trigger premature ventricular beats (PVB) as well as ventricular tachyarrhythmia (VT).24 Regarding vulnerable genotypes, studies have shown that risk of Efavirenz-mediated long QT markedly increased in homozygous carriers of the CYP2B6*6 allele.9,18 In addition to ART regimens, polypharmacy might cause interactions and provoke dysrhythmias. With this in mind, we excluded patients who currently used medications other than ART, illicit drugs or smoked tobacco. Overall, the multi factorial nature of QT prolongation and various confounding factors in HIV-AIDS is a challenge but caution should be kept when prescribing specific ART components such as Efavirenz.

Prolonged QT might also appear secondary to autonomic dysregulation, which is associated with both virus-mediated and ART-induced alterations in sympatho-vagal balance. Although diminished autonomic reserve usually occurs in the early stages of HIV infection, severe dysfunction emerges in late phase of the disease. However, the duration of disease and the longevity of treatment regimens were both similar in Efavirenz group compared with non-Efavirenz patients. Previous studies have reported considerable decline in HRV of HIV patients on ART regimens, particularly NNRTIs like Efavirenz.25 SDANN is a measure of total HRV indicating the effects of both sympathetic and parasympathetic derives. General metabolic disturbance either due to HIV infection or to medications may contribute to low parasympathetic activity and low SDANN.26 Moreover, lipodystrophy occurs commonly in patients receiving Efavirenz.27 Some researchers declared that hypercholesterolemia, and hyperglycaemia diminish the HRV regardless of the duration of ART, which is discordant with our findings.28 In fact, we observed greater prevalence of low HRV (SDANN) and prolonged QT in Efavirenz patients (against non-Efavirenz group) who were treated for more than 5 years. A meta-analysis by Mc Intosh RC found that HRV was lower in a cohort of HIV-infected young adults who received ART than those without ART.29
HRV serves as a marker of cardiopulmonary fitness. Multiple studies have focused on exercise-based interventions in HIV-infected individuals. Grant and colleagues examined the influence of a regular aerobic exercise protocol on SDANN and other measures of HRV. Their controlled trial found improvement of maximal volume of oxygen uptake (VO2max) and incremental values of HRV after 16 weeks. Recent studies have shown an inverse relationship between biomarkers of inflammation such as IL-6, CRP, and tumor necrosis factor, and HRV. Similar associations have been shown for the coagulation cascade factors like D-dimer in HIV patients. 

In the present study, Efavirenz affected male subjects more than females. In fact, total significant dysrhythmia and most of the components except AV block and sinus pause were more frequent in males on Efavirenz than in males not on Efavirenz. Nevertheless, females on Efavirenz did not differ from females of non-Efavirenz group with regard to any type of dysrhythmia. Given these gender differences, it seems that higher levels of inflammatory cytokines accompanied by electrical remodeling in patients with active HIV infection rather than those with controlled status potential alterations in ion channels and autonomic drive in HIV infected males under ART were indicated in few studies. Thus, precursors of dysrhythmia like reduced HRV and prolonged QT were associated with prominent inflammation in HIV infected men. Our findings of long QT are in line with these reports. However, subgroup analysis demonstrated longer QTc in males under Efavirenz as compared with males in control group. Furthermore, there was a high rate of prolonged QTc in patients with longer treatment courses (>5 vs. <5 years).

A greater PAC burden (>500 bp24h) was found in male HIV-AIDS patients who received Efavirenz-containing regimens. This finding was not mentioned in any of the prior studies, which evaluated ART-associated dysrhythmia. We did not detect any cases with complete AV block, but second-degree blocks were similar in the two groups. Therefore, as described in prior studies, Efavirenz may not contribute to an increased rate of blocks and other conduction disturbances in HIV-infected patients.

Despite general similarity of the two groups at baseline, a higher proportion of non-Efavirenz patients received PI. Treatment with PIs was not associated with dysrhythmia or significant ECG changes. This is in accordance with studies by Charbit et al. and Fiorentini et al. Despite case reports and initial studies supporting such an effect, cumulative evidence has shown that QTc prolongation is not directly related to PIs.

Multivariate model in our study showed a trend toward significant decrease of dysrhythmia with greater CD4 counts which was close to previous reports. This may underline the role of optimal treatment for reducing dysrhythmias particularly prolonged QT.

We excluded patients with a history of diabetes, hypertension, coronary artery disease, current smoking, dysrhythmia, chronic kidney disease, and family history of sudden cardiac death, since these factors might increase susceptibility to ischemic heart disease, which could lead to dysrhythmias. Therefore, included patients constituted a relatively homogeneous population of young to middle-aged HIV patients who were apparently free of cardiovascular disease. Although the pathogenesis of dysrhythmia involves multiple pathways and aetiologies, we aimed to restrict underlying risk factors, particularly overt structural heart diseases. Since potential confounding factors were eliminated, we could demonstrate effects attributable to antiretroviral regimens.

5 | STUDY LIMITATIONS

The present investigation was a single-center study. However, it was conducted in a tertiary referral hospital with specialized facilities for HIV patients. The retrospective design poses some caveats pertaining to causality and temporal linkages between exposure and outcomes. Methodological barriers prevented us to evaluate if Efavirenz, and other ART drugs, are risk factors or independently causative. The total number of malignant dysrhythmias such as VT was low which may mask the true impact of the Efavirenz. Therefore, further studies are required to evaluate all types of rhythm disorders secondary to Efavirenz. Ventricular and atrial ectopic dysrhythmias usually vary with time, which mandates monitoring for longer periods such as 48 hours or even 1 week.

As discussed earlier, we did not measure levels of inflammatory biomarkers to evaluate their impact. Clinical implication of the observed outcomes, which are precursors of dysrhythmia remains to be elucidated in larger studies with, extended follow-up times. Cardiovascular events such as syncope, sudden arrest, and stroke should be targeted. Furthermore, whether continuing Efavirenz or substituting with another drug prevents cardiac events remains uncertain. Our findings might be restricted to a particular subgroup of otherwise healthy HIV patients, which limits generalizability. Additionally, the method for detection of dysrhythmias has limitations for relatively rare or infrequent episodes of certain disorders.

6 | CONCLUSION

Patients exposed to Efavirenz had higher prevalence of high PVC, high PAC, and total significant dysrhythmia but similar proportions of low HRV (SDANN). However, Efavirenz group had lower HRV as measured via SDNN with a borderline significance. Efavirenz regimen, mean heart rate, male gender and lower CD4 counts were independent predictors of total dysrhythmia. Efavirenz regimen increased QT, which was prominent in subgroup of males while females were not affected. Furthermore, majority of impacts exerted via Efavirenz were predominantly observed in males rather than females. Use of ambulatory electrocardiographic monitoring may improve screening and diagnosis of at risk individuals. However, the subgroup of HIV-infected patients who may benefit most from screening of dysrhythmia, the appropriate time intervals, methods, cost-effectiveness, follow-up protocols, and management algorithms are unclear.

ACKNOWLEDGMENTS

The authors wish to show their appreciation to staff of infectious disease ward as well as those facilitating the access to HIV registry in Imam Khomeini medical center.
CONFLICT OF INTEREST
The authors declare that they had no type of competing interests.

AUTHOR CONTRIBUTIONS
Reza Mollazadeh and Seyed-Ali Dehghan-Manshadi provided the core concept of the case report and performed treatment of the patient as well as supervising the study. Zahra Hosseini and Ali Akbari collected the data. Zahra Hosseini, Mehrnaz Mohebi, and Saeed Ghodsi wrote the draft and revised the manuscript. Zahra Hosseini, Seyed-Ali Sadre Bafghi, Seyed-Ali Dehghan-Manshadi, and Mehrnaz Mohebi prepared the tables and Figures. Saeed Ghodsi and Zahra Hosseini performed statistical analysis. All authors read and approved the final manuscript.

INFORMED CONSENT
We obtained written informed consent from all patients for publishing the clinical data and related aspects.

DATA AVAILABILITY STATEMENT
Data sharing will be applicable to this article according to probable

REFERENCES
1. UNAIDS. Ending AIDS: Progress towards the 90–90-90 Targets. Global AIDS Update, 2017. Accessed April 03, 2018. http://www.unaids.org/sites/default/files/media_asset/Global_AIDS_update_2017_en.pdf
2. Islamic Republic of Iran AIDS progress report on monitoring of the United Nations General Assembly Special session on HIV and AIDS. Accessed February 2016. http://www.unaids.org/sites/default/files/OHIV/country/documents/IRIN_narrative_report_2015.pdf
3. Tseng ZH, Secemsky EA, Dowdy D, et al. Sudden cardiac death in patients with human immunodeficiency virus infection. J Am Coll Cardiol. 2012;59(21):1891-1896. https://doi.org/10.1016/j.jacc.2012.02.024
4. Fettig J, Swaminathan M, Murrill CS, Kaplan JE. Global epidemiology of HIV. Infectious Disease Clinics of North America. 2014;28(3):323-337. https://doi.org/10.1016/j.idc.2014.05.001.
5. Updated recommendations on first-line and second-line antiretroviral regimens and post-exposure prophylaxis and recommendations on early infant diagnosis of HIV: interim guidelines. Geneva: World Health Organization, 2018. https://apps.who.int/iris/bitstream/handle/10665/277395/WHO-CDS-HIV-18.51-eng.pdf?ua=1
6. Islam FM, Wu J, Jansson J, Wilson DP. Relative risk of cardiovascular disease among people living with HIV: a systematic review and meta-analysis. HIV Med. 2012;13(8):453-468. https://doi.org/10.1111/j.1468-1293.2012.00994.x
7. Rosenblatt L, Farr AM, Johnston SS, Nkhome ET. Risk of cardiovascular events among patients initiating efavirenz-containing versus efavirenz-free antiretroviral regimens. Open Forum Infectious Diseases. 2016;3(2). https://doi.org/10.1093/ofid/ofw061.
8. Wu KC, Bhondelkhan F, Haberlen SA, et al. Associations between QT interval subcomponents, HIV serostatus, and inflammation. Ann Noninvasive Electrocardiol. 2020;25(2):e12705. https://doi.org/10.1111/ane.12705
9. Brouillette J, Cyr S, Fiset C. Mechanisms of arrhythmia and sudden cardiac death in patients with HIV infection. Can J Cardiol. 2019;35(3):310-319. https://doi.org/10.1016/j.cjca.2018.12.015
10. Adagé AS, Casey SA, Kuskowski MA, Zenovich AG, Maron BJ. Spectrum and prognostic significance of arrhythmias on ambulatory Holter electrocardiogram in hypertrophic cardiomyopathy. J Am Coll Cardiol. 2005;45(5):697-704.
11. Umetani K, Singer DH, McCratty R, Atkinson M. Twenty-four hour time domain heart rate variability and heart rate: relations to age and gender over nine decades. J Am Coll Cardiol. 1998;31(3):593-601.
12. Shaffer F, Ginsberg JP. An overview of heart rate variability metrics and norms. Frontiers in Public Health. 2017;5. https://doi.org/10.3389/fpubh.2017.00258.
13. Vandenberk B, Vandel E, Robyns T, Vandenberghhe J, Garweg C, Foulon V, Ector J, Willems R. Which QT correction formulae to use for QT monitoring?. Journal of the American Heart Association. 2016;5(6). https://doi.org/10.1161/jaha.116.003264.
14. Johnson NJ, Ackerman MJ. QTc: how long is too long?. British Journal of Sports Medicine. 2009;43(9):657-662. https://doi.org/10.1136/bjsm.2008.054734.
15. Levey AS, Greene T, Kusek JW, Beck GL, MDRD Study Group. A simplified equation to predict glomerular filtration rate from serum creatinine (abstract). J Am Soc Nephrol. 2000;11:155A.
16. Ogunmodede J, Kolo P, Katibi I, Omosoto A. The use of first line highly active anti-retroviral therapy (haart) is not associated with QTc prolongation in haart patients. Ethiopian Journal of Health Sciences. 2016;27(6):1206-1213. https://doi.org/10.1111/jcic.13032
17. Chirino P, Petrosillo N, Di Stefano A, et al. QTc interval prolongation in HIV-infected patients: a case–control study by 24-hour Holter ECG recording. BMC Cardiovasc Disord. 2012;12:12.
18. Abdelhady AM, Shugg T, Thong N, et al. Efavirenz inhibits the human ether-a-go-go related current (hERG) and induces QT interval prolongation in CYP2B6*6*6 allele carriers. J Cardiovasc Electrophysiol. 2016;27(10):1206-1213. https://doi.org/10.1111/jce.13032
19. Chinillo P, Petrosillo N. QT interval prolongation and antiretroviral treatment: another point of Interest [with reply]. Clin Infect Dis. 2007;44(10):1388-1391.
20. Charbit B, Rosier A, Bollens D, et al. Relationship between HIV protease inhibitors and QTc interval duration in HIV-infected patients: a cross-sectional study. Br J Clin Pharmacol. 2009;67(1):76-82. https://doi.org/10.1111/j.1365-2125.2008.03322.x
21. Castillo R, Pedalino RP, El-Sherif N, Turitto G. Efavirenz-associated QT prolongation and torsade de pointes arrhythmia. Annals of Pharmacotherapy. 2002;36(6):1006-1008. https://doi.org/10.1345/aph.1a454.
22. Hreiche R, Morissette P, Turgeon J. Drug-induced long QT syndrome in women: review of current evidence and remaining gaps. Gend Med. 2008;5(2):124-135.
23. Perrin MJ, Subbiah RN, Vandenbergh J, Hill AP. Human ether-a-go-go related gene (hERG) K+ channels: function and dysfunction. Prog Biophys Mol Biol. 2008;98(2-3):137-148.
24. Heravi AS, Etzkorn LH, Urbanek JK, et al. HIV infection is associated with variability in ventricular repolarization. Circulation. 2020;141(3):176-187. https://doi.org/10.1161/circulationaha.119.043042.
25. Wongcharoen W, Khienprasit K, Phrommintikul A, Sukonthasarn A, Chattiakorn N. Heart rate variability and heart rate turbulence in HIV-infected patients receiving combination antiretroviral therapy. Ann Noninvasive Electrocardiol. 2013;18(5):450-456.
26. Lebech AM, Kristoffersen US, Mehlsen J, et al. Autonomic dysfunction in HIV patients on antiretroviral therapy: studies of heart rate variability. Clin Physiol Funct Imaging. 2007;27(6):363-367.
27. Maggiolo F. Efavirenz: a decade of clinical experience in the treatment of HIV. J Antimicrob Chemother. 2009;64(5):910-928. https://doi.org/10.1093/jac/dkp334

28. Askgaard G, Kristoffersen US, Mehlsen J, Kronborg G, Kjaer A, Lebech A-M. Decreased heart rate variability in HIV positive patients receiving antiretroviral therapy: importance of blood glucose and cholesterol. PLoS One. 2011;6(5):e20196. https://doi.org/10.1371/journal.pone.0020196

29. McIntosh RC. A meta-analysis of HIV and heart rate variability in the era of antiretroviral therapy. Clinical Autonomic Research. 2016;26(4):287-294. https://doi.org/10.1007/s10286-016-0366-6.

30. Grant CC, Viljoen M, Janse van Rensburg DC, Wood PS. Heart rate variability assessment of the effect of physical training on autonomic cardiac control. Ann Noninvas Electrocardiol. 2012;17:219-229.

31. Young LC, Roediger MP, Grandits G, et al. Relationship between inflammatory and coagulation biomarkers and cardiac autonomic function in HIV-infected individuals. Biomark Med. 2014;8(9):1073-1083.

32. RC MI, Lobo JD, Hurwitz BE. Current assessment of heart rate variability and QTc interval length in HIV/AIDS. Curr Opin HIV AIDS. 2017;12(6):528-533.

33. Sloan RP, McCreath H, Tracey KJ, Sidney S, Liu K, Seeman T. RR interval variability is inversely related to inflammatory markers: the CARDIA study. Mol Med. 2007;13:178-184. https://doi.org/10.2119/2006-00112.Sloan

34. Wu KC, Zhang L, Haberlen SA, et al. Predictors of electrocardiographic QT interval prolongation in men with HIV. Heart. 2019;105:559-565.

35. Kuller LH, Tracy R, Beloso W, et al. Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med. 2008;5(10):e203. https://doi.org/10.1371/journal.pmed.0050203

36. Cardoso J, Mota-Miranda A, Cruz A, et al. Dysrhythmic profile of human immunodeficiency virus infected patients. Int J Cardiol. 1995;49(3):249-255.

37. Das MK. Cardiac arrhythmias in HIV disease. Cardiovasc Rev Rep. 2002;23(4):208-12-226.

38. Saidi AS, Moodie DS, Garson A Jr, et al. Electrocardiography and 24-hour electrocardiographic ambulatory recording (Holter monitor) studies in children infected with human immunodeficiency virus type 1. The pediatric pulmonary and cardiac complications of vertically transmitted HIV-1 infection study group. Pediatr Cardiol. 2000;21(3):189-196.

39. Anson BD, Weaver JG, Ackerman MJ, et al. Blockade of HERG channels by HIV protease inhibitors. Lancet. 2005;365:682-686.

40. Busti AJ, Tsikouris JP, Peeters MJ, et al. A prospective evaluation of the effect of atazanavir on the QTc interval and QTc dispersion in HIV-positive patients. HIV Med. 2006;7(5):317-322.

41. Hunt K, Hughes CA, Hills-Nieminen C. Protease inhibitor-associated QT interval prolongation. Ann Pharmacother. 2011;45(12):1544-1550. https://doi.org/10.1345/aph.1Q422

42. QaQa AY, Shaaban H, DeBari VA, Phung S, Slim J, Costeas CA, Perez G, Shamoon FE. Viral load and cd4+ cell count as risk factors for prolonged qt interval in hiv-infected subjects: a cohort-nested case-control study in an outpatient population. Cardiology. 2010;117(2):105-111. https://doi.org/10.1159/000320216.